A new Health Link security offering for principal investigators will grant additional research security similar to what is currently provided to research coordinators....
The US Food and Drug Administration (FDA) is outlining a standardized approach for collecting and reporting on race and ethnicity data in clinical trials and studies in a new draft guidance document....
Diseases that degrade the mind strike at the very heart of our humanity. Unfortunately, such diseases aren’t rare. Strokes, infections, and chronic conditions like diabetes can all cause lasting damage to the brain. And more than 6 million Americans are living with Alzheimer’s disease and...
The pediatric cancer specialists at UW Health Kids American Family Children’s Hospital are part of a national research team that combines two scientific fields — genomics and immunotherapy — in search of cures for the most hard-to-treat cancers....
The Carbone Center, which is attached to the School of Medicine and Public Health, is one of the six original comprehensive cancer centers in the United States. ...
The study, recently published in the Nature journal Scientific Reports, showed that as levels of calprotectin, an inflammatory marker, increased in the volunteer study participants’ stool samples, so did the amount of amyloid plaque accumulating in the brains of those with Alzheimer’s disease....
Dr. Howard Bailey, director of the Madison-based cancer treatment and research organization, spoke this week during a meeting of the Wisconsin Technology Council’s Innovation Network. He emphasized the progress being made in understanding and developing more effective treatments for the disease, as well as new...
Lupus significantly and disproportionately impacts Black, Hispanic and Asian patients, but these populations are underrepresented in clinical trials for the disease....
Testing a person’s blood for a type of protein called phosphorylated tau, or p-tau, could be used to screen for Alzheimer’s disease with “high accuracy,” even before symptoms begin to show, a new study suggests....
As new treatments reach the market, a problem appears: real-world research shows dissatisfying outcomes and access disparities. One US study reveals that within the early years of a novel interventional device usage, women fare significantly worse than men, even after accounting for underlying differences....
